Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB)

SOL #: BAA-75N93026R00008Pre-Solicitation

Overview

Buyer

Health And Human Services

National Institutes Of Health

NATIONAL INSTITUTES OF HEALTH NIAID

BETHESDA, MD, 20892, United States

Place of Performance

Place of performance not available

NAICS

Research and Development in the Physical (541715)

PSC

Health R&D Services; Health Care Services; Applied Research (AN12)

Set Aside

No set aside specified

Original Source

https://sam.gov/opp/0dd47ca15cdb4684af691141890a5414/view

Timeline

Posted

May 18, 2026

Response Deadline

Jun 2, 2026, 7:00 PM

Qualification Details

Fit reasons

NAICS alignment with historical contract wins in similar service areas.
Scope strongly matches core technical capabilities and delivery model.

Risks

Past performance thresholds may require one additional teaming partner.
Potential clarification needed on staffing minimums before bid/no-bid.

Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is issuing a presolicitation for the Immune Mechanisms of Protection Against Mycobacterium tuberculosis Center (IMPAc-TB) program. This initiative seeks to accelerate TB vaccine development by characterizing protective immune responses and advancing related tools and resources. The Broad Agency Announcement (BAA) is anticipated to be available on June 2, 2026. Any responsible offeror may submit a proposal.

Purpose & Scope

The IMPAc-TB program aims to support research that characterizes tissue-specific and systemic immune responses preventing or containing Mtb infection, and to advance tools and resources for TB vaccine development. This includes understanding the impact of HIV/SIV infection on responses to Mtb and TB vaccines. Research will involve human samples, clinical studies, at least one animal model, and computational data integration. New approach methods (NAMs) like organoid or ex vivo systems may also be considered. The program will identify immune signatures, evaluate protective antigens/epitopes, and support the translation of knowledge to advance vaccine approaches, including mucosal vaccines.

Key Requirements

Research utilizing human samples and/or clinical studies.
Inclusion of at least one animal model.
Computational data integration and modeling for cross-comparative analyses.
Potential use of NAMs (e.g., organoid, ex vivo systems).
Support for translation of knowledge to advance vaccine approaches.
Refinement of fit-for-purpose animal models for vaccine testing.
Clinical research through cohorts or trials, enabling backtranslation.

Contract Details

Type: Cost reimbursement, completion type contracts.
Awards: Anticipated two to three awards.
Performance Start: Approximately September 1, 2027.
Duration: Up to five years.
Estimated Annual Program Cost: $10.5 million (total).
Estimated Annual Per Award Cost: Approximately $5 million (total costs).
Cross-Contract Collaboration: Contractors will set aside $300,000/year (years 2-5) for collaborative studies, proposed and evaluated by NIH Program staff, PIs, and an External Scientific Advisory Group.

Submission & Timeline

BAA Availability: On/about June 2, 2026, via SAM.gov.
Submission Method: Proposals must be submitted via the NIAID electronic Contract Proposal Submission (eCPS) website (https://ecps.nih.gov/). Facsimile or e-mail submissions are not acceptable.